Cardiorenal actions of TRV120027, a novel ß-arrestin-biased ligand at the angiotensin II type i receptor, in healthy and heart failure canines: A novel therapeutic strategy for acute heart failure

Guido Boerrigter, Michael W. Lark, Erin J. Whalen, David G. Soergel, Jonathan D. Violin, John C Jr. Burnett

Research output: Contribution to journalArticle

101 Citations (Scopus)

Abstract

Background - The angiotensin II type 1 receptor (AT1R) plays a key role in regulating cardiorenal function. Classic "unbiased" AT1R antagonists block receptor coupling to both G αq and β-arrestin- mediated signals, which desensitize G-protein signaling as well as transduce G-protein-independent signals. TRV120027 is a novel β-arrestin- biased AT1R ligand, which engages β-arrestins while blocking G-protein signaling. At the AT1R, TRV120027 can inhibit angiotensin II-mediated vasoconstriction, whereas, through β-arrestin coupling, increase cardiomyocyte contractility. We defined for the first time the acute cardiorenal actions of TRV120027 in healthy and heart failure (HF) canines. Methods and Results - Healthy and HF canines (induced by tachypacing) were anesthetized. After instrumentation and equilibration, a 30-minute baseline clearance was performed, followed by further clearance with escalating doses of intravenous TRV120027 (0.01, 0.1, 1, 10, and 100 μg/kg per minute) and a 30-minute washout. In healthy canines, TRV120027 decreased pulmonary capillary wedge pressure and systemic and renal vascular resistances, while increasing cardiac output, renal blood flow, glomerular filtration rate, and urinary sodium excretion. In HF canines, TRV120027 decreased mean arterial pressure, right atrial pressure, and pulmonary capillary wedge pressure, systemic and renal vascular resistances and increased cardiac output and renal blood flow. Glomerular filtration rate and urinary sodium excretion were maintained. Conclusions - We report for the first time the cardiorenal actions of the novel β-arrestin- biased AT1R ligand TRV120027. In both normal and HF canines, TRV120027 demonstrated cardiac unloading actions while preserving renal function. With this beneficial pharmacological profile, TRV120027 represents a novel strategy for the treatment of HF.

Original languageEnglish (US)
Pages (from-to)770-778
Number of pages9
JournalCirculation: Heart Failure
Volume4
Issue number6
DOIs
StatePublished - Nov 2011

Fingerprint

Arrestin
Angiotensin Receptors
Canidae
Heart Failure
Ligands
Angiotensin Type 1 Receptor
GTP-Binding Proteins
Pulmonary Wedge Pressure
Therapeutics
Renal Circulation
Glomerular Filtration Rate
Kidney
Cardiac Output
Vascular Resistance
Sodium
Arrestins
Angiotensin II Type 1 Receptor Blockers
sarcosine-arginyl-valyl-tyrosyl-isoleucyl-histidyl-prolyl-alanine
Atrial Pressure
Vasoconstriction

Keywords

  • Angiotensin II
  • Drugs
  • Heart failure
  • Pharmacology
  • Receptors

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Cite this

Cardiorenal actions of TRV120027, a novel ß-arrestin-biased ligand at the angiotensin II type i receptor, in healthy and heart failure canines : A novel therapeutic strategy for acute heart failure. / Boerrigter, Guido; Lark, Michael W.; Whalen, Erin J.; Soergel, David G.; Violin, Jonathan D.; Burnett, John C Jr.

In: Circulation: Heart Failure, Vol. 4, No. 6, 11.2011, p. 770-778.

Research output: Contribution to journalArticle

@article{88b820b0cba145b0be0813648390e204,
title = "Cardiorenal actions of TRV120027, a novel {\ss}-arrestin-biased ligand at the angiotensin II type i receptor, in healthy and heart failure canines: A novel therapeutic strategy for acute heart failure",
abstract = "Background - The angiotensin II type 1 receptor (AT1R) plays a key role in regulating cardiorenal function. Classic {"}unbiased{"} AT1R antagonists block receptor coupling to both G αq and β-arrestin- mediated signals, which desensitize G-protein signaling as well as transduce G-protein-independent signals. TRV120027 is a novel β-arrestin- biased AT1R ligand, which engages β-arrestins while blocking G-protein signaling. At the AT1R, TRV120027 can inhibit angiotensin II-mediated vasoconstriction, whereas, through β-arrestin coupling, increase cardiomyocyte contractility. We defined for the first time the acute cardiorenal actions of TRV120027 in healthy and heart failure (HF) canines. Methods and Results - Healthy and HF canines (induced by tachypacing) were anesthetized. After instrumentation and equilibration, a 30-minute baseline clearance was performed, followed by further clearance with escalating doses of intravenous TRV120027 (0.01, 0.1, 1, 10, and 100 μg/kg per minute) and a 30-minute washout. In healthy canines, TRV120027 decreased pulmonary capillary wedge pressure and systemic and renal vascular resistances, while increasing cardiac output, renal blood flow, glomerular filtration rate, and urinary sodium excretion. In HF canines, TRV120027 decreased mean arterial pressure, right atrial pressure, and pulmonary capillary wedge pressure, systemic and renal vascular resistances and increased cardiac output and renal blood flow. Glomerular filtration rate and urinary sodium excretion were maintained. Conclusions - We report for the first time the cardiorenal actions of the novel β-arrestin- biased AT1R ligand TRV120027. In both normal and HF canines, TRV120027 demonstrated cardiac unloading actions while preserving renal function. With this beneficial pharmacological profile, TRV120027 represents a novel strategy for the treatment of HF.",
keywords = "Angiotensin II, Drugs, Heart failure, Pharmacology, Receptors",
author = "Guido Boerrigter and Lark, {Michael W.} and Whalen, {Erin J.} and Soergel, {David G.} and Violin, {Jonathan D.} and Burnett, {John C Jr.}",
year = "2011",
month = "11",
doi = "10.1161/CIRCHEARTFAILURE.111.962571",
language = "English (US)",
volume = "4",
pages = "770--778",
journal = "Circulation: Heart Failure",
issn = "1941-3297",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Cardiorenal actions of TRV120027, a novel ß-arrestin-biased ligand at the angiotensin II type i receptor, in healthy and heart failure canines

T2 - A novel therapeutic strategy for acute heart failure

AU - Boerrigter, Guido

AU - Lark, Michael W.

AU - Whalen, Erin J.

AU - Soergel, David G.

AU - Violin, Jonathan D.

AU - Burnett, John C Jr.

PY - 2011/11

Y1 - 2011/11

N2 - Background - The angiotensin II type 1 receptor (AT1R) plays a key role in regulating cardiorenal function. Classic "unbiased" AT1R antagonists block receptor coupling to both G αq and β-arrestin- mediated signals, which desensitize G-protein signaling as well as transduce G-protein-independent signals. TRV120027 is a novel β-arrestin- biased AT1R ligand, which engages β-arrestins while blocking G-protein signaling. At the AT1R, TRV120027 can inhibit angiotensin II-mediated vasoconstriction, whereas, through β-arrestin coupling, increase cardiomyocyte contractility. We defined for the first time the acute cardiorenal actions of TRV120027 in healthy and heart failure (HF) canines. Methods and Results - Healthy and HF canines (induced by tachypacing) were anesthetized. After instrumentation and equilibration, a 30-minute baseline clearance was performed, followed by further clearance with escalating doses of intravenous TRV120027 (0.01, 0.1, 1, 10, and 100 μg/kg per minute) and a 30-minute washout. In healthy canines, TRV120027 decreased pulmonary capillary wedge pressure and systemic and renal vascular resistances, while increasing cardiac output, renal blood flow, glomerular filtration rate, and urinary sodium excretion. In HF canines, TRV120027 decreased mean arterial pressure, right atrial pressure, and pulmonary capillary wedge pressure, systemic and renal vascular resistances and increased cardiac output and renal blood flow. Glomerular filtration rate and urinary sodium excretion were maintained. Conclusions - We report for the first time the cardiorenal actions of the novel β-arrestin- biased AT1R ligand TRV120027. In both normal and HF canines, TRV120027 demonstrated cardiac unloading actions while preserving renal function. With this beneficial pharmacological profile, TRV120027 represents a novel strategy for the treatment of HF.

AB - Background - The angiotensin II type 1 receptor (AT1R) plays a key role in regulating cardiorenal function. Classic "unbiased" AT1R antagonists block receptor coupling to both G αq and β-arrestin- mediated signals, which desensitize G-protein signaling as well as transduce G-protein-independent signals. TRV120027 is a novel β-arrestin- biased AT1R ligand, which engages β-arrestins while blocking G-protein signaling. At the AT1R, TRV120027 can inhibit angiotensin II-mediated vasoconstriction, whereas, through β-arrestin coupling, increase cardiomyocyte contractility. We defined for the first time the acute cardiorenal actions of TRV120027 in healthy and heart failure (HF) canines. Methods and Results - Healthy and HF canines (induced by tachypacing) were anesthetized. After instrumentation and equilibration, a 30-minute baseline clearance was performed, followed by further clearance with escalating doses of intravenous TRV120027 (0.01, 0.1, 1, 10, and 100 μg/kg per minute) and a 30-minute washout. In healthy canines, TRV120027 decreased pulmonary capillary wedge pressure and systemic and renal vascular resistances, while increasing cardiac output, renal blood flow, glomerular filtration rate, and urinary sodium excretion. In HF canines, TRV120027 decreased mean arterial pressure, right atrial pressure, and pulmonary capillary wedge pressure, systemic and renal vascular resistances and increased cardiac output and renal blood flow. Glomerular filtration rate and urinary sodium excretion were maintained. Conclusions - We report for the first time the cardiorenal actions of the novel β-arrestin- biased AT1R ligand TRV120027. In both normal and HF canines, TRV120027 demonstrated cardiac unloading actions while preserving renal function. With this beneficial pharmacological profile, TRV120027 represents a novel strategy for the treatment of HF.

KW - Angiotensin II

KW - Drugs

KW - Heart failure

KW - Pharmacology

KW - Receptors

UR - http://www.scopus.com/inward/record.url?scp=84856343982&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856343982&partnerID=8YFLogxK

U2 - 10.1161/CIRCHEARTFAILURE.111.962571

DO - 10.1161/CIRCHEARTFAILURE.111.962571

M3 - Article

C2 - 21835984

AN - SCOPUS:84856343982

VL - 4

SP - 770

EP - 778

JO - Circulation: Heart Failure

JF - Circulation: Heart Failure

SN - 1941-3297

IS - 6

ER -